Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Medullary thyroid cancer: options for systemic therapy of metastatic disease?

Literature DB >> 16549818

Medullary thyroid cancer: options for systemic therapy of metastatic disease?

Renato G Martins, Joseph G Rajendran, Peter Capell, David R Byrd, David A Mankoff.

Abstract

Entities: Disease

Mesh：

Year: 2006 PMID： 16549818 DOI： 10.1200/JCO.2005.05.4106

Source DB: PubMed Journal: J Clin Oncol ISSN： 0732-183X Impact factor: 44.544

Keyword Cloud
Cited

× No keyword cloud information.

11 in total

1. The Treatment of Advanced Thyroid Cancer in the Age of Novel Targeted Therapies.

Authors: Roy Lirov; Francis P Worden; Mark S Cohen
Journal: Drugs Date: 2017-05 Impact factor: 9.546

2. Effect of an Outreach Programme on Vandetanib Safety in Medullary Thyroid Cancer.

Authors: Lars Bastholt; Michael C Kreissl; Dagmar Führer; Ana L Maia; Laura D Locati; Léa Maciel; Yi Wu; Kevin N Heller; Alan Webster; Rossella Elisei
Journal: Eur Thyroid J Date: 2016-09-10

Review 3. Cancer treatment according to BRCA1 and BRCA2 mutations.

Authors: Kara N Maxwell; Susan M Domchek
Journal: Nat Rev Clin Oncol Date: 2012-07-24 Impact factor: 66.675

4. A novel RET inhibitor with potent efficacy against medullary thyroid cancer in vivo.

Authors: Abbas K Samadi; Ridhwi Mukerji; Anuj Shah; Barbara N Timmermann; Mark S Cohen
Journal: Surgery Date: 2010-12 Impact factor: 3.982

5. Cancer Imaging and Therapy with Bispecific Antibody Pretargeting.

Authors: David M Goldenberg; Jean-Francois Chatal; Jacques Barbet; Otto Boerman; Robert M Sharkey
Journal: Update Cancer Ther Date: 2007-03

6. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial.

Authors: Samuel A Wells; Bruce G Robinson; Robert F Gagel; Henning Dralle; James A Fagin; Massimo Santoro; Eric Baudin; Rossella Elisei; Barbara Jarzab; James R Vasselli; Jessica Read; Peter Langmuir; Anderson J Ryan; Martin J Schlumberger
Journal: J Clin Oncol Date: 2011-10-24 Impact factor: 44.544

7. Non-toxic fragment of botulinum neurotoxin type A and monomethyl auristatin E conjugate for targeted therapy for neuroendocrine tumors.

Authors: Jason Whitt; Won S Hong; Rahul R Telange; Chee Paul Lin; James Bibb; David J Beebe; Herbert Chen; Renata Jaskula-Sztul
Journal: Cancer Gene Ther Date: 2020-02-07 Impact factor: 5.987